ASCO 2025 interim analysis from the JAVELIN Bladder Medley phase 2 trial, avelumab + sacituzumab govitecan, avelumab monotherapy, first-line maintenance treatment in patients with advanced urothelial ...

In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at ...

House Bill 3057 lifts barriers to CAR T cell therapy access in rural Texas, allowing more patients to receive care closer to home.

Join Tracy Byrd at the 2025 Gala to support Southeast Texas families battling pediatric cancer with Go 4 The Bell. Event includes a concert, auctions, and more.

BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated the muscle layer—is one of the earliest forms of cancer ...

We conducted a retrospective cohort study of patients with bladder cancer registered in the Registro Hospitalar de Câncer da Fundação Oncocentro de São Paulo, a large state-wide database. Eligibility ...

A new preclinical study unveils a more powerful and effective immunotherapy for bladder cancer and other solid tumours.

The AI tool may help clarify which men with high-risk prostate cancer benefit from treatment intensification.

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. bladder cancer patients has crossed the FDA finish line as UroGen Pharma ...

El Paso's new $340M cancer center receives $65M boost from Texas Legislature, bringing advanced care to the Borderplex region by 2028.